Core Viewpoint - Sol-Gel Technologies Ltd. (SLGL) has experienced a recent downtrend, losing 8.4% over the past two weeks, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest and positive earnings outlook from analysts [1]. Group 1: Technical Analysis - A hammer chart pattern was formed in the last trading session, indicating that bulls may have countered the bears, suggesting potential support for the stock [1]. - The hammer pattern signals a possible bottom in a downtrend, indicating that selling pressure may be exhausting [2]. - Hammer candles can appear on various timeframes and are used by both short-term and long-term investors, but should be combined with other bullish indicators for confirmation [2]. Group 2: Fundamental Analysis - There has been a positive trend in earnings estimate revisions for SLGL, with a 31.3% increase in the consensus EPS estimate for the current year over the last 30 days, indicating expected better earnings [3]. - SLGL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which typically outperform the market [3]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are beginning to improve, further supporting the potential for a trend reversal [3].

Core Viewpoint - Sol-Gel Technologies Ltd. (SLGL) has received an upgrade to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily based on a company's changing earnings picture, specifically the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Sol-Gel Technologies indicates a positive outlook on its earnings, which is expected to positively impact its stock price [4][6]. Impact of Earnings Estimate Revisions - There is a strong correlation between changes in earnings estimates and near-term stock price movements, making the Zacks rating system valuable for investors [5][7]. - Rising earnings estimates for Sol-Gel Technologies suggest an improvement in the company's underlying business, which should lead to higher stock prices as investors recognize this trend [6]. Performance of Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - Sol-Gel Technologies' upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11]. Earnings Estimate Data - For the fiscal year ending December 2024, Sol-Gel Technologies is expected to earn -$0.57 per share, reflecting a year-over-year change of 43.6% [9]. - Over the past three months, the Zacks Consensus Estimate for Sol-Gel Technologies has increased by 31.3%, indicating a positive trend in earnings expectations [9].

Core Insights - Sol-Gel Technologies is extending its cash runway into Q1 2026 following recent transactions and cost-cutting measures [1] - The company is conducting a Phase 3 clinical trial for SGT-610 targeting Gorlin Syndrome, with topline results expected by Q2 2026 [1][2] - Sol-Gel has signed multiple licensing agreements for its products TWYNEO and EPSOLAY in Europe and South Africa, with plans for further expansion into Latin America and other regions [2][5] Financial Performance - Total revenue for Q2 2024 was $5.4 million, a significant increase from $0.6 million in Q2 2023 [6] - Research and development expenses decreased to $2.4 million from $5.3 million in the same period last year, attributed to various cost-saving measures [7] - The company reported a net income of $1.9 million for Q2 2024, compared to a net loss of $6.0 million in Q2 2023 [8] Clinical Developments - The Phase 3 study for SGT-610 is ongoing with approximately 140 subjects involved, and results are anticipated in Q2 2026 [2][5] - A proof-of-concept study for SGT-210 in Darier disease is also in progress, targeting a market potential of $200 million to $300 million [3][5] Management Changes - Mr. Mori Arkin is set to become the interim CEO as of January 1, 2025, pending shareholder approval, following a management realignment [4] - The current CEO, Dr. Alon Seri-Levy, will step down at the end of 2024 but will continue as a consultant for at least one year [4] Licensing and Market Expansion - Sol-Gel has signed six initial license agreements for TWYNEO and EPSOLAY, expecting upfront and milestone payments of up to $3.7 million [2] - The company anticipates launching TWYNEO and EPSOLAY in new territories by 2027 and 2026, respectively, with projected annual royalty revenues starting at $1 million to $2 million in 2026 and growing to approximately $10 million by 2030 [2]

分组1 - Sol-Gel Technologies Ltd. reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of a loss of $0.20 per share, and showing improvement from a loss of $0.22 per share a year ago, resulting in an earnings surprise of 135% [1] - The company generated revenues of $5.43 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 414.98%, compared to revenues of $0.59 million in the same quarter last year [2] - Sol-Gel Technologies has outperformed consensus EPS estimates two times over the last four quarters, indicating a positive trend in revenue performance [2] 分组2 - The stock has underperformed the market, losing about 62% since the beginning of the year, while the S&P 500 has gained 16.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $0.74 million, and for the current fiscal year, it is -$0.83 on revenues of $3.35 million [7] - The Medical - Generic Drugs industry, to which Sol-Gel Technologies belongs, is currently ranked in the top 17% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Core Insights - Sol-Gel Technologies is extending its cash runway into Q1 2026 following recent transactions and cost-cutting measures [1] - The company is conducting a Phase 3 clinical trial for SGT-610 targeting Gorlin Syndrome, with topline results expected by Q2 2026 [1][4] - Sol-Gel has signed new licensing agreements for its products TWYNEO and EPSOLAY in Europe and South Africa, with plans for further agreements in Latin America and other regions [2][4] Financial Performance - Total revenue for Q2 2024 was $5.4 million, a significant increase from $0.6 million in Q2 2023 [5] - Research and development expenses decreased to $2.4 million in Q2 2024 from $5.3 million in Q2 2023, attributed to various cost-saving measures [6] - General and administrative expenses were reduced to $1.4 million in Q2 2024 from $1.8 million in Q2 2023 [7] - The company reported a net income of $1.9 million for Q2 2024, compared to a net loss of $6.0 million in Q2 2023 [7] Cash Position - As of June 30, 2024, Sol-Gel had $15.6 million in cash and cash equivalents, and $14.9 million in marketable securities, totaling $30.5 million [8] - The company expects its cash resources to support operations into Q1 2026 [8] Clinical Development - The Phase 3 trial for SGT-610 is ongoing with approximately 140 subjects involved, and results are anticipated in Q2 2026 [2] - SGT-610 targets a market exceeding $300 million annually if approved [2][4] - The proof-of-concept study for SGT-210 in Darier disease is also ongoing, with market potential estimated between $200 million to $300 million [2][4] Management Changes - Mr. Mori Arkin will assume the role of interim CEO starting January 1, 2025, pending shareholder approval [3] - The current CEO, Dr. Alon Seri-Levy, will step down effective December 31, 2024, but will continue as a consultant [3]

Core Insights - Sol-Gel Technologies, Ltd. has entered into six exclusive license agreements for the commercialization of its dermatology products TWYNEO and EPSOLAY across multiple European countries, indicating strong market expansion potential [8][9] - The company is focused on developing innovative treatments for skin diseases, with TWYNEO approved for acne vulgaris and EPSOLAY approved for inflammatory lesions of rosacea [3][9] - Sol-Gel is conducting a Phase 3 clinical trial for SGT-610, a treatment for Gorlin syndrome, which is expected to enhance its competitive position in the dermatology market [8][10] Company Overview - Sol-Gel Technologies specializes in identifying, developing, and commercializing drug products for skin diseases, with a focus on innovative formulations [3][8] - The company has developed TWYNEO, a unique topical cream combining tretinoin and benzoyl peroxide, and EPSOLAY, which utilizes a patented technology for encapsulating benzoyl peroxide [2][9] - The company’s pipeline includes additional clinical trials for SGT-610 and SGT-210, targeting rare skin conditions and aiming for improved safety profiles [10] Market Expansion - The new license agreements cover major European markets including Germany, the UK, France, and others, reflecting a strategic move to enhance product availability [8][9] - Sol-Gel is set to receive upfront and regulatory milestone payments totaling up to low 7-digit USD, along with future royalties from net sales, backed by commitments to minimum annual sales [8][9] - The regulatory submissions in these territories will be managed by Sol-Gel's partners, with the company providing assistance in the preparation of these submissions [8]

Financial Performance - Sol-Gel Technologies Ltd. reported a quarterly loss of $0.23 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, representing an earnings surprise of -53.33% [1] - The company posted revenues of $0.47 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 64.15%, compared to year-ago revenues of $0.76 million [2] - The current consensus EPS estimate for the coming quarter is -$0.17 on $0.3 million in revenues, and for the current fiscal year, it is -$0.67 on $2.4 million in revenues [7] Stock Performance - Sol-Gel Technologies shares have declined approximately 32.1% since the beginning of the year, while the S&P 500 has gained 11.2% [3] - The company has surpassed consensus EPS estimates two times over the last four quarters, but has only topped consensus revenue estimates once in the same period [2] Industry Outlook - The Medical - Generic Drugs industry, to which Sol-Gel Technologies belongs, is currently in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the stock's performance [5]

Financial Results for the First Quarter Year Ended March 31st, 2024 NESS ZIONA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large- category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the first quarter ended March 31, 2024 and provided a ...

Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration of up to $115 million. Sol-Gel recently initiated a proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease. Highly encouraging clinical response for SGT-210 from a Compassionate use treatment for a pediatric patient suf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...